Your browser doesn't support javascript.
loading
Interlaboratory comparison of a multiplex immunoassay that measures human serum IgG antibodies against six-group B streptococcus polysaccharides.
Le Doare, Kirsty; Gaylord, Michelle A; Anderson, Annaliesa S; Andrews, Nick; Baker, Carol J; Bolcen, Shanna; Felek, Arif; Giardina, Peter C; Grube, Christopher D; Hall, Tom; Hallis, Bassam; Izu, Alane; Madhi, Shabir A; Maniatis, Pete; Matheson, Mary; Mawas, Fatme; McKeen, Andrew; Rhodes, Julia; Alston, Bailey; Patel, Palak; Schrag, Stephanie; Simon, Raphael; Tan, Charles Y; Taylor, Stephen; Kwatra, Gaurav; Gorringe, Andrew.
Afiliación
  • Le Doare K; Centre for Neonatal and Paediatric Infection, Institute for Infection and Immunity, St George's, University of London, London, UK.
  • Gaylord MA; Makerere University Johns Hopkins University, Kampala, Uganda.
  • Anderson AS; UK Health Security Agency, Porton Down, UK.
  • Andrews N; Pfizer Vaccine Research & Development, Pearl River, NY, USA.
  • Baker CJ; Pfizer Vaccine Research & Development, Pearl River, NY, USA.
  • Bolcen S; Immunisation and Vaccine Preventable Diseases Division, United Kingdom Health Security Agency (UKHSA), London, UK.
  • Felek A; Department of Pediatrics, Division of Infectious Disease, McGovern Medical School and UT Health, Houston, TX, USA.
  • Giardina PC; The Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
  • Grube CD; Vaccine Division, Scientific Research & Innovation Group, MHRA, Potters Bar, UK.
  • Hall T; Pfizer Vaccine Research & Development, Pearl River, NY, USA.
  • Hallis B; Pfizer Vaccine Research & Development, Pearl River, NY, USA.
  • Izu A; Centre for Neonatal and Paediatric Infection, Institute for Infection and Immunity, St George's, University of London, London, UK.
  • Madhi SA; UK Health Security Agency, Porton Down, UK.
  • Maniatis P; South African Medical Research Council: Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Matheson M; Department of Science/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.
  • Mawas F; South African Medical Research Council: Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • McKeen A; Department of Science/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.
  • Rhodes J; The Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
  • Alston B; UK Health Security Agency, Porton Down, UK.
  • Patel P; Vaccine Division, Scientific Research & Innovation Group, MHRA, Potters Bar, UK.
  • Schrag S; Pfizer Global Biometrics & Data Management, Pearl River, NY, USA.
  • Simon R; The Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
  • Tan CY; Eagle Global Scientific, Atlanta, GA, USA.
  • Taylor S; The Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
  • Kwatra G; The Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
  • Gorringe A; Pfizer Vaccine Research & Development, Pearl River, NY, USA.
Hum Vaccin Immunother ; 20(1): 2330138, 2024 Dec 31.
Article en En | MEDLINE | ID: mdl-38608170
ABSTRACT
Measurement of IgG antibodies against group B streptococcus (GBS) capsular polysaccharide (CPS) by use of a standardized and internationally accepted multiplex immunoassay is important for the evaluation of candidate maternal GBS vaccines in order to compare results across studies. A standardized assay is also required if serocorrelates of protection against invasive GBS disease are to be established in infant sera for the six predominant GBS serotypes since it would permit the comparison of results across the six serotypes. We undertook an interlaboratory study across five laboratories that used standardized assay reagents and protocols with a panel of 44 human sera to measure IgG antibodies against GBS CPS serotypes Ia, Ib, II, III, IV, and V. The within-laboratory intermediate precision, which included factors like the lot of coated beads, laboratory analyst, and day, was generally below 20% relative standard deviation (RSD) for all six serotypes, across all five laboratories. The cross-laboratory reproducibility was < 25% RSD for all six serotypes, which demonstrated the consistency of results across the different laboratories. Additionally, anti-CPS IgG concentrations for the 44-member human serum panel were established. The results of this study showed assay robustness and that the resultant anti-CPS IgG concentrations were reproducible across laboratories for the six GBS CPS serotypes when the standardized assay was used.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Síndrome de Guillain-Barré Límite: Humans / Infant Idioma: En Revista: Hum Vaccin Immunother Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Síndrome de Guillain-Barré Límite: Humans / Infant Idioma: En Revista: Hum Vaccin Immunother Año: 2024 Tipo del documento: Article